Ownership of Arising Intellectual Property Sample Clauses
Ownership of Arising Intellectual Property. All right, title and interest in and to any data, Patents, and extensions thereof, Know-How and other information created, developed, or arising on or after the Effective Date and pertaining to Licensed Products shall be solely owned by Monopar. For the avoidance of doubt, Arising Intellectual Property generated through CMC, Quality, data, or clinical observations will be owned by Monopar. As of the Effective Date, at its own cost, Monopar shall have the full and exclusive benefit of, and right to apply for and obtain, patents or other similar forms of protection in respect of any part or parts of the subject-matter of the Licensed Patents throughout the world, and the right to claim priority from the Licensed Patents.
Ownership of Arising Intellectual Property. 7.2.1 Arising Intellectual Property conceived and/or reduced to practice entirely by the employee, student or agent of one Party shall vest with that Party in accordance with its applicable policies and collective agreements. Arising Intellectual Property made jointly by employees, students or agents of both Parties shall be jointly owned by the Parties, based on each of their contributions.
7.2.2 Joint Owners shall manage commercialization activities in respect of jointly owned Arising Intellectual Property as per the terms of an inventions management agreement to be negotiated on commercially reasonable terms between the Joint Owners acting in good faith.
7.2.3 Each Party hereby grants to the other Party a non-exclusive fully-paid worldwide, royalty free license to use the Arising Intellectual Property for their own internal research and educational non-commercial purposes and shall ensure that the appropriate and necessary agreements and documents are obtained from their employees, students and/or agents in order to grant such rights of usage.
7.2.4 The University agrees to grant to the Collaborator an option to negotiate an exclusive royalty bearing license to make, use or sell any Arising Intellectual Property owned by the University. The Collaborator shall have three (3) months from disclosure of any Arising Intellectual Property to notify the University of its desire to enter into such license which agreement shall be negotiated in good faith within a period not to exceed six (6) months from the Collaborator’s notification of its intention to exercise said option or such period of time as the parties may mutually agree. OPTION A: include exclude
7.2.5 The Collaborator agrees to grant to the University an option to negotiate an exclusive royalty bearing license to make, use or sell any Arising Intellectual Property owned by. The University shall have three (3) months from disclosure of any Arising Intellectual Property to notify the University of its desire to enter into such license which agreement shall be negotiated in good faith within a period not to exceed six (6) months from the University notification of its intention to exercise said option or such period of time as the parties may mutually agree. OPTION B: include exclude
Ownership of Arising Intellectual Property. Inventorship of Arising Intellectual Property will be determined in accordance with principles of U.S. patent law. GCLC shall own all Arising Intellectual Property invented solely by GCLC employees, and any Arising Intellectual Property invented jointly with employees of Artiva and/or Merck shall be jointly owned between GCLC and Artiva and/or Merck.
Ownership of Arising Intellectual Property. As between the Parties, ownership of all Collaboration Know-How will be as follows:
(a) Ionis will be the sole owner of any (i) Collaboration Know-How that is developed or invented solely by Representatives of Ionis or its Affiliates or its or their licensees (other than Otsuka), Sublicensees, or Subcontractors, or any Persons contractually required to assign or license such Collaboration Know-How to Ionis or any Affiliate of Ionis (“Ionis Collaboration Know-How”), and (ii) Patent Rights that Cover the Ionis Collaboration Know-How (“Ionis Collaboration Patent Rights”), and will retain all of its rights thereto, subject to any rights or licenses expressly granted by Xxxxx to Otsuka under this Agreement.
Ownership of Arising Intellectual Property. Any Intellectual Property Rights that are invented, developed, created, improved or authored pursuant to this Agreement shall be owned as follows:
(a) Cypress shall own all right, title and interest in and to any modifications, improvements or derivative works of any of the Licensed Technology and all Intellectual Property Right therein, made or conceived of during the term of this Agreement (“Cypress Technology.”)
(b) Subject to Cypress’s rights in Cypress Technology, Customer shall own all right, title and interest in and to any Intellectual Property Rights therein that are modifications, improvements or derivative works of any Superconducting Technology, made or conceived during the term of this agreement. “Superconducting Technology” shall mean technology in possession of superconducting properties, such as zero electrical resistance, when operated at cryogenic temperatures, and comprised of superconducting devices, such as Xxxxxxxxx junctions.
Ownership of Arising Intellectual Property. Roche will own all rights to Intellectual Property in the Research Results. The Research Results shall include the Deliverables. For the avoidance of any misunderstanding it is agreed that in no case shall Partner have the right to use the Research Results, except as contemplated under the Work Plan. The Research Results will be stored in separate databases at Partner. At Roche’s request, all Research Results will be destroyed by Partner and Partner shall not keep any copy of such data. Partner shall confirm the destruction of all Research Results to Roche in writing.
Ownership of Arising Intellectual Property. Ownership of Know-How, and all intellectual property rights therein, that is conceived, reduced to practice, discovered, developed, or made by or on behalf of either Party or any Third Parties acting on their behalf (or any of their Representatives, Affiliates, licensees, or Sublicensees) in the course of performing activities under this Agreement (“Inventions”) will be as follows:
(a) Licensee will solely own (or retain ownership of) all Inventions, other than Product Inventions, that are conceived, reduced to practice, discovered, developed, or made solely by or on behalf of Licensee or any Third Party acting on its behalf (or any of its Representatives, Affiliates, or Sublicensees but excluding, for the avoidance of doubt, Licensor and its sublicensees), and all intellectual property rights therein (“Arising Licensee IP”).
(b) Licensor will solely own (or retain ownership of) (i) all Inventions that are conceived, reduced to practice, discovered, developed, or made solely by or on behalf of Licensor or Licensee or jointly by Licensor or Licensee or any Third Parties acting on their behalf (or any of their Representatives, Affiliates, or licensees or Sublicensees), and all intellectual property rights therein, directed to the composition of matter of Licensed Products, including improvements thereof, or methods of use of Licensed Products, including combinations of active ingredients or other products using Licensed Products and improvements thereof, or methods of manufacturing Licensed Products and improvements thereof (the “Product Inventions”) and (ii) all other Inventions that are conceived, reduced to practice, discovered, developed, or made solely by or on behalf of Licensor (or any of its Representatives or Affiliates), and all intellectual property rights therein (collectively, “Arising Licensor IP”).
(c) Licensor will [***]on the one hand, and Licensee [***], on the other hand, and all intellectual property rights therein (“Arising Joint IP”) outside the Territory, and [***] inside the Territory. 14.2
Ownership of Arising Intellectual Property. Ownership of Know-How, and all intellectual property rights therein, that is conceived, reduced to practice, discovered, developed, or made by or on behalf of either Party or any Third Parties acting on their behalf (or any of their Affiliates, licensees, or Sublicensees) in the course of performing activities under this Agreement (“Program IP”) will be as follows:
(a) Licensor will solely own (or retain ownership of) (i) all Program IP that is conceived, reduced to practice, discovered, developed, or made solely by or on behalf of Licensor or Licensee or jointly by Licensor or Licensee or any Third Parties acting on their behalf (or any of their Affiliates or licensees or Sublicensees), and all intellectual property rights therein, related to a Licensed Product (the “Licensor Product-Related Program IP”) and (ii) all other Program IP that is conceived, reduced to practice, discovered, developed, or made solely by or on behalf of Licensor (or any of its Affiliates), and all intellectual property rights therein (collectively, “Licensor Program IP”).
(b) Licensee will [***], and all intellectual property rights therein (“Licensee Program IP”).
(i) Licensor will [***], on the one hand, and Licensee [***], on the other hand, and all intellectual property rights therein (“Joint IP”) outside Japan, and [***] inside Japan.
Ownership of Arising Intellectual Property. The parties agree that all Arising Intellectual Property relating to Quick-Med Technology shall be the property of Quick-Med, and that Quick-Med shall have the sole right to apply for, prosecute, and obtain patents that contain disclosures and claims relating only to Quick-Med Technology. The parties further agree that all Arising Intellectual Property relating to KCI Technology shall be the property of KCI, and that KCI shall have the sole right to apply for, prosecute, and obtain patents that contain disclosures and claims relating only to KCI Technology. The parties further agree that Arising Intellectual Property that relates both to Quick-Med Technology and to KCI Technology (“Joint Arising IP”) shall be the property of KCI, and that KCI shall have the sole right to apply for, prosecute, and obtain patents that contain disclosures and claims relating to Joint Arising IP. KCI grants Quick-Med a worldwide royalty-free exclusive (even as to KCI) license to Joint Arising IP outside of the Field with the right to sublicense Joint Arising IP outside of the Field to a third party. For the avoidance of doubt, any modification or improvement to the antimicrobial chemistry or formulation shall be the property of Quick-Med.
Ownership of Arising Intellectual Property. As between the Parties, ownership of all Collaboration Know-How will be as follows:
(a) Ionis will be the sole owner of any (i) Collaboration Know-How that is developed or invented solely by Representatives of Ionis or its Affiliates or its or their licensees (other than Thera), Sublicensees, or subcontractors, or any Persons contractually required to assign or license such Collaboration Know-How to Ionis